Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma, Inc. - Common Stock (NQ:SILO)

1.185 -0.065 (-5.20%)
Streaming Delayed Price Updated: 11:28 AM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,614
Open 1.220
Bid (Size) 1.150 (2)
Ask (Size) 1.210 (1)
Prev. Close 1.250
Today's Range 1.150 - 1.233
52wk Range 0.7700 - 4.500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Final Preclinical Study for PTSD Treatment SPC-15
Via Investor Brand Network
Exposures Product Safety

Performance

YTD
+24.7%
+24.7%
1 Month
-12.5%
-12.5%
3 Month
+33.1%
+33.1%
6 Month
+7.7%
+7.7%
1 Year
-37.6%
-37.6%

More News

Read More
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Secures USPTO Patent for PTSD Treatment SPC-15
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Provisional Patent for SPC-15 Dual-Action Treatment
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Early Data on SP-26 Ketamine Implant Study
Via Investor Brand Network
Topics Animal Testing
Exposures Animal Testing
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Bolsters Intellectual Property with New Patent Filing for PTSD Treatment
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Silo Pharma Shares Are Surging Today: What's Going On?
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Crude Oil Down 1%; US Weekly Jobless Claims Decline
Via Benzinga
Exposures Fossil Fuels
US Stocks Down; Acuity Brands Posts Weak Revenue
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Strengthens Patent Portfolio with Approval for PTSD Treatment SPC-15
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Ketamine Implant Development with Pharmacokinetic Study
Via Investor Brand Network
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partners with Kymanox to Advance Ketamine Implant Therapeutic for Chronic Pain
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Is Silo Pharma Stock Gaining Today?
Via Benzinga

Frequently Asked Questions

Is Silo Pharma, Inc. - Common Stock publicly traded?
Yes, Silo Pharma, Inc. - Common Stock is publicly traded.
What exchange does Silo Pharma, Inc. - Common Stock trade on?
Silo Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Silo Pharma, Inc. - Common Stock?
The ticker symbol for Silo Pharma, Inc. - Common Stock is SILO on the Nasdaq Stock Market
What is the current price of Silo Pharma, Inc. - Common Stock?
The current price of Silo Pharma, Inc. - Common Stock is 1.185
When was Silo Pharma, Inc. - Common Stock last traded?
The last trade of Silo Pharma, Inc. - Common Stock was at 03/31/25 11:28 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.